In a real‑world observational cohort of 66 patients with treatment‑resistant bipolar I/II depression, four sub‑anaesthetic intravenous ketamine infusions over two weeks produced statistically and clinically significant, progressive reductions in depressive symptoms, suicidality and anxiety (mean QIDS‑SR16 reduction 6.08; p<0.0001). Response and remission rates were 35% and 20% respectively, with generally good tolerability (4.5% treatment‑emergent hypomania, no mania or psychosis).
- Published
- Journal
- Bipolar Disorders
- Authors
- Fancy, F., Rodrigues, N. B., Di Vincenzo, J. D., Chau, E. H., Sethi, A., Husain, M. I., Gill, H., Tabassum, A., Mckenzie, A., Phan, L., McIntyre, R. S., Rosenblat, J. D.